Paclitaxel Carboplatin

PR) and median survival was 26 mo. The 3-yr survival probability is 0.47 (64). Because dose escalation was limited to 74 Gy without reaching a maximally tolerated dose, a further trial is underway to find the true MTD of dose-escalated thoracic radiation with concurrent carboplatin-paclitaxel-based chemotherapy. 

Socinski M A, Rosenman JG, Schell MJ, et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall-cell lung carcinoma a modified Phase I trial. Cancer 2000 89(3) 534-542. 

Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer a California Cancer Consortium phase II trial. J Clin Oncol 2001 19(2) 442-447. 

Socinski MA, Halle J, Schell MJ, et al. Induction (I) and Concurrent (C) Carboplatin/Paclitaxel (C/P) with Dose-Escalated Thoracic Conformal Radiotherapy (TCRT) in Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) A Phase Eli Trial. ProcAm Soc Clin Oncol 2000 19 Abstract 1940. 

CDDP/docetaxel H CDDP/gemcItabine El Carboplatin/paclitaxel... 

The possible impact of co-administered chemotherapies and radiation therapy on the PK of cetuximab was furthermore assessed using the population PK approach, as described in Section 14.6. The co-administered chemotherapies included cisplatin, carboplatin, paclitaxel, doxorubicin, irinotecan, and gemcitabine. The results of the analysis indicate that neither the co-administered chemotherapies nor radiation therapy had a significant impact on the PK of cetuximab. This finding suggests that the potential for PK-based drug-drug interactions with cetuximab is low. 

Newer platinum-based combinations have proven effective in Phase-II studies of patients with advanced disease. Carboplatin/paclitaxel (response rate 23%) and cisplatin/gemcitabine (response rate 24%) have figured prominently [142] [143], The carboplatin/paclitaxel combination appears remarkably active in the induction setting, as Dang et al. reported response rates of 95% [144], and also when given weekly with concurrent radiotherapy... 

Squalamine has been tested in mammary, ovary, and lung cancer xenograft mouse models [20,23-26]. Results sho ved that squalamine alone had a modest effect on tumor growth delay and in some cases it resulted in decreased number of lung metastases. However, in most studies, squalamine treatment was more efficacious when combined with previously established anticancer agents such as cyclophosphamide, cisplatin, carboplatin, paclitaxel, 5-fluorouracil, or genestein, or with radiation therapy. 

Blumenschein, G., Ludwig, C., Thomas, G., Tan, E., Fanucchi, M., Soantoro, A., Crawford, J., Breton, J., O Brien, M., and Khun, F. (2005). A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer. Lung Cancer 49(Suppl. 2) S30. 

Ovary Carboplatin paclitaxel Topotecan liposomal doxorubicin (caelyx)... 

CP carboplatin-paclitaxel 5-FU 5-fluorouracil HNSCC head and neck squamous cell carcinoma IFL irinotecan, 5-fluorouraciI, leucovorin N number of patients NR not reported CRC colorectal cancer NSCLC nonsmall cell lung cancer OS overall survival PFS progression-free survival RR response rate RT radiotherapy. 

Joyce, a psychologist. Ovarian cancer, stage 3, diagnosed in 2004 at age fifty-eight. (Treatment surgery, hysterectomy, splenectomy, and colon resection. Chemo carboplatin, paclitaxel, cisplatin, gemcitabine, topotecan, doxorubicin.)... 

Kearns CM, Belani CP, Erkmen K, Zuhowski M, Hiponia D, Ergstrom C, Ramanthan R, Trenn M, Aisner J, Ergorin MJ, Reduced platelet toxicity with combination carboplatin paclitaxel pharmacodynamic modulation of carboplatin associated thrombocytopenia, Proc Am Soc Clin Oncol (1995) 14,170,... 

Reck M, Krzakowski M, Chmielowska E, Sebastian M, Hadler D, Fox T, et al. A ranomized, double-blind, placebo-controUed phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-smaU cell lung cancer. Lung Cancer 2013 82(3) 441-8. 

---